Results 41 to 50 of about 3,684 (214)

Inflammatory back pain as an unusual manifestation of Takayasu arteritis: a case report

Reumatismo
Takayasu arteritis and spondyloarthritis are two rheumatological diseases whose co-existence is well-documented in the literature. Data on the presence of inflammatory back pain in Takayasu arteritis without a diagnosis of spondyloarthritis, however, is
F.I. Gorial, N.I. Awadh, A. Al-Shakarchi, G. Al-Gburi   +3 more
doaj   +1 more source

Cutaneous and rheumatological manifestations of reactive arthritis: A case report

Clinical Case Reports, 2022
Reactive arthritis is a rare form of spondyloarthropathies occurring after genital or enteric infection. It is most often self‐limited but can progress to chronic spondylarthritis.
Maroua Slouma, Siwar Ben Dhia, Rim Dhahri, Noureddine Litaiem, Leila Metoui, Imen Gharsallah, Bassem Louzir   +6 more
doaj   +1 more source

T cells, the Next Big Target in Axial Spondyloarthritis?

Arthritis &Rheumatology, EarlyView.
Axial spondyloarthritis (axSpA) is a chronic inflammatory disease characterized by complex immune dysregulation, with T cells playing a central role in its pathogenesis. In this review, we synthesize current knowledge on diverse T cell subsets in axSpA, their pathogenic mechanisms, and emerging therapeutic strategies targeting these cells. We highlight
Mansi K. Aparnathi, Nigil Haroon
wiley   +1 more source

Chronic pyogenic spondylitis in patients with spinal gout: a case series and literature review [PDF]

Travmatologiâ i Ortopediâ Rossii
Background. Spinal gout is a rare and poorly described group of noninfectious inflammatory spinal lesions characterized by the deposition of monosodium urate crystals in the epidural space, paravertebral soft tissues, and by facet joints damage. There is
Arkadiy A. Vishnevskiy, Denis G. Naumov, Mikhail M. Shchelkunov, Tatiana A. Novitskaya   +3 more
doaj   +1 more source

Real‐World Effectiveness and Safety of Upadacitinib in Combination With Biologic Therapy in Patients With Inflammatory Bowel Disease

JCC Plus, Volume 1, Issue 3, May 2026.
ABSTRACT Background Upadacitinib is a selective Janus kinase 1 inhibitor that has demonstrated rapid onset and efficacy in patients with moderate‐to‐severe Crohn's disease (CD) and ulcerative colitis (UC). Here, we describe the real‐world efficacy and safety of upadacitinib in combination with biologic therapies for IBD.
Nicole M. Garcia, Uma Mahadevan, Sara Lewin, Rishika Chugh   +3 more
wiley   +1 more source

Differences in the course of coxitis in men and women with early axial spondyloarthritis

Научно-практическая ревматология, 2023
Introduction. Currently, there is a small number of studies devoted to the differences in the manifestations of axial spondyloarthritis (axSpA) in men and women, and there are no studies assessing the frequency of coxitis in axSpA in patients of ...
E. M. Agafonova, Sh. Erdes, T. V. Dubinina, A. B. Demina, A. V. Smirnov   +4 more
doaj   +1 more source

Temporal Trends in and Associations With Nonsteroidal Anti‐inflammatory Drug Prescription in Adult and Pediatric Patients With Inflammatory Bowel Disease

Arthritis Care &Research, Volume 78, Issue 4, Page 439-448, April 2026.
Objective Recent inflammatory bowel disease (IBD) treatment guidelines have recommended against nonsteroidal anti‐inflammatory drug (NSAID) use despite prevalent musculoskeletal symptoms and opioid overuse in this population. Given the discordance between changing national guidelines and potential clinical utility, we sought to assess national temporal
Adam S. Mayer, Rui Xiao, Andrew Grossman, Meenakshi Bewtra, Michael D. George, Pamela F. Weiss   +5 more
wiley   +1 more source

Evaluation of the Performance of Large Language Models in the Management of Axial Spondyloarthropathy: Analysis of EULAR 2022 Recommendations

Diagnostics
Introduction: Guidelines have great importance in revealing complex and chronic conditions such as axial spondyloarthropathy. The aim of this study is to compare the answers given by various large language models to open-ended questions created from ASAS–
Ahmet Usen, Ozlem Kuculmez
doaj   +1 more source

Nouveaux traitements biologiques et synthétiques de fond pour les spondylarthropathies [New synthetic and biologic treatments for spondylarthritis]

, 2016
The only biological treatments recognized and reimbursed for spondylarthritis in Switzerland are anti TNF. Other effective agents in rheumatoid arthritis were found to be of little use in this indication.
Zufferey, P.
core   +1 more source

Oral Celastrol Nanomedicine Targeting Intestinal Antigen‐Presenting Cells to Effectively Mitigate Autoimmune Uveitis via Gut‐Retina Axis

Advanced Science, Volume 13, Issue 20, 9 April 2026.
Oral nanoCEL exhibits effective intestinal targeting of antigen‐presenting cells and restores the Th17/Treg balance in lymph nodes and spleen, ultimately protecting the blood‐retinal barrier by inhibiting peripheral immune cell infiltration and suppressing retinal glial cell activation.
Jinrun Chen, Yuqin Wu, Bofei Xu, Jiabei Hou, Yijing Li, Yuhan Hu, Yutuo Zhu, Wenqiao Zhang, Shuqi Feng, Huanting Jin, Yuchen Cheng, Yuanyuan Jin, Jianhong Zhou, Xingyi Li   +13 more
wiley   +1 more source